ID   LNCaP-PDR2
AC   CVCL_C0RS
SY   LNCaP PDR2; LN-PDR2
DR   cancercelllines; CVCL_C0RS
DR   GEO; GSM2650011
DR   GEO; GSM2650012
DR   GEO; GSM2650013
DR   GEO; GSM2650014
DR   GEO; GSM2650015
DR   GEO; GSM2650016
DR   PRIDE; PXD006561
DR   Wikidata; Q112930020
RX   PubMed=29739788;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:85993; Palbociclib (Ibrance).
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0395 ! LNCaP
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=29739788; DOI=10.1158/1078-0432.CCR-18-0410;
RA   de Leeuw R., McNair C., Schiewer M.J., Poudel-Neupane N., Brand L.J.,
RA   Augello M.A., Li Z., Cheng L.C., Yoshida A., Courtney S.M.,
RA   Hazard E.S., Hardiman G., Hussain M.H., Diehl J.A., Drake J.M.,
RA   Kelly W.K., Knudsen K.E.;
RT   "MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.";
RL   Clin. Cancer Res. 24:4201-4214(2018).
//